Glycophorin A as a biological dosimeter for radiation dose to the bone marrow from iodine-131
- Univ. of California, San Francisco, CA (United States)
- Univ. of Pittsburgh, PA (United States); and others
The frequency of peripheral blood erythrocyte variants exhibiting allelic loss of glycophorin A (N/M antigen) has been used previously as a biological dosimeter to assess somatic mutations in bone marrow cells from external whole-body irradiation. The aim of the present study was to determine whether this marker could be used as a measure of bone marrow genotoxicity induced by {sup 131}I in the treatment of thyroid cancer. Flow cytometry of immunolabeled erythrocytes was performed to enumerate glycophorin A variants before and after eight therapy doses of {sup 131}I administered to five patients with differentiated thyroid carcinoma. Bone marrow radiation exposure from each dose was calculated from the integrated retention of {sup 131}I in the whole body and in the blood. In addition, the accumulated dose to the bone marrow received from earlier {sup 131}I therapy was calculated for each patient. Regression analysis was performed on the frequency of two glycophorin A variant cell types (N/O and N/N) as a function of accumulated dose to the bone marrow. Frequency of N/O variant cells showed a significant dose-related increase with a slope of 10.9 x 10{sup -6} per sievert. This dose effect is about one-half that previously observed after whole-body external irradiation at high dose rate. This decreased response could be explained by the low dose rate of the radiation to the bone marrow from {sup 131}I. 24 refs., 2 figs., 2 tabs.
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- W-7405-ENG-48
- OSTI ID:
- 535362
- Journal Information:
- Radiation Research, Journal Name: Radiation Research Journal Issue: 6 Vol. 147; ISSN 0033-7587; ISSN RAREAE
- Country of Publication:
- United States
- Language:
- English
Similar Records
I{sup 131} therapy induces persistent radiation-dose dependent increases in glycophorin a locus somatic mutations in bone marrow stem cells
Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma
Persistent genetic damage in blood and bone marrow cells following radioiodine therapy
Journal Article
·
Tue Oct 31 23:00:00 EST 1995
· Environmental and Molecular Mutagenesis
·
OSTI ID:115113
Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma
Journal Article
·
Wed Dec 31 23:00:00 EST 1975
· J. Clin. Endocrinol. Metab., v. 42, no. 1, pp. 105-111
·
OSTI ID:4036544
Persistent genetic damage in blood and bone marrow cells following radioiodine therapy
Journal Article
·
Tue Oct 31 23:00:00 EST 1995
· Environmental and Molecular Mutagenesis
·
OSTI ID:115132